Reactions Weekly

, Volume 1714, Issue 1, pp 7–7 | Cite as

Dizziness is a dose-related AE following lasmiditan for migraine

Clinical study


  1. Tepper SJ, et al. Characterization of Dizziness Treatment-Emergent Adverse Events After Lasmiditan: Findings of the SAMURAI and SPARTAN Phase 3 Acute Migraine Treatment Trials . 60th Annual Scientific Meeting of the American Headache Society : abstr. PS38, 28 Jun 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations